MEDICO REMEDIES Latest Share Price (MEDICO)
TODAY IN ONE LINE
MEDICO edged up 0.9% on light volume, in line with Nifty's 0.1% move.
With a market cap of ₹329.36 Cr., it trades at a P/E of 26.66. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
MEDICO REMEDIES flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 36.5% YoY
- ●High Capital EfficiencyROCE of 15.6% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 17.4%
- ●High Promoter HoldingPromoters hold 61.4% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.25x
- ●Promoter BuyingPromoters increased holdings by 61.38% QoQ
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Sales ContractionQuarterly sales dropped 66.4% YoY
- ●Rising Receivables vs SalesReceivables grew 15.1% outpacing sales growth of 4.2%
Latest MEDICO REMEDIES News
What changed recently?
Recent events, corporate actions, and announcements.
MEDICO REMEDIES valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for MEDICO REMEDIES, framed against the sector median so the premium or discount is obvious at a glance.
MEDICO REMEDIES trades at a P/E of 26.66× and P/B of 4.86×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
MEDICO REMEDIES technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for MEDICO REMEDIES — derived from the latest tape, not yesterday's close.
MEDICO REMEDIES last traded at ₹39.87 with an intraday range of ₹39–₹40.19 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹39.87| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 42.75 | +2.88 | +7.23% |
| R3 | 41.56 | +1.69 | +4.25% |
| R2 | 40.88 | +1.01 | +2.52% |
| R1 | 40.37 | +0.50 | +1.26% |
| PIVOT | 39.69 | -0.18 | -0.46% |
| CURRENT | 39.87 | — | — |
| S1 | 39.18 | -0.69 | -1.72% |
| S2 | 38.50 | -1.37 | -3.44% |
| S3 | 37.99 | -1.88 | -4.71% |
| S4 | 36.80 | -3.07 | -7.69% |
MEDICO is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: ₹39–₹39.91
Trading Inside opening range
MEDICO REMEDIES financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for MEDICO REMEDIES — consolidated or standalone — with margins, YoY growth and key ratios inline.
MEDICO REMEDIES reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹329.36 Cr. and reported EPS of ₹0.30.
MEDICO REMEDIES segment analysis : revenue and profit mix.
Disclosed business segments at MEDICO REMEDIES with their share of revenue and profit, switchable between consolidated and standalone reporting.
MEDICO REMEDIES discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for MEDICO REMEDIES.
Our AI distills the core fundamental drivers supporting MEDICO REMEDIES, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
MEDICO REMEDIES's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
TTM EPS grew 36.5% YoY, demonstrating strong earnings momentum and operational efficiency gains.
ROE 19.0% and ROCE 23.1% exceed sector averages, signaling efficient capital deployment.
Debt-to-equity ratio 0.0025x exceptionally low, ensuring robust financial flexibility and stability.
Promoter holding 61.38% signals strong governance commitment and long-term vision alignment.
TTM revenue growth 37.5% significantly outpaces pharmaceutical sector median growth rates.
Key Risks.
Latest quarterly sales declined 66.37% YoY and PAT declined 80.80% YoY, momentum reversed sharply.
Operating margin 6.75% lags peer benchmarks, limiting pricing power and profitability sustainability.
P/E ratio 26.82x elevated relative to modest operating margins and growth sustainability concerns.
Zero dividend yield reduces appeal for income-focused and conservative investor segments.
Market cap ₹329.36 Cr smallest among peers, constraining scale and market influence significantly.
Flip Conditions.
Valuation risk. a P/E above 35 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 12% would indicate weaker capital compounding.
MEDICO REMEDIES peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — MEDICO REMEDIES is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
MEDICO REMEDIES chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for MEDICO REMEDIES — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
MEDICO REMEDIES delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for MEDICO REMEDIES over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in MEDICO REMEDIES stood at 50.7% of traded volume, against a 20-day average of 51.1%.
MEDICO REMEDIES announcements: results, concalls, ratings, M&A.
Filings MEDICO REMEDIES sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
MEDICO REMEDIES files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 39 documents below.
General Updates
Medico Remedies Limited has informed the Exchange about Book Closure Dates.
Shareholders meeting
Medico Remedies Limited has informed the Exchange regarding Notice of undefined to be held on September 22, 2026
Outcome of Board Meeting
Medico Remedies Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Bagging/Receiving of orders/contracts
Medico Remedies Limited has informed the Exchange about Bagging/Receiving of orders/contracts
Price movement
Significant movement in price has been observed in Medico Remedies Limited. The Exchange, in order to ensure that investors have latest relevant…
Investor decks & rating reports.
MEDICO REMEDIES dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue MEDICO REMEDIES has declared, sequenced by announce and record date.
MEDICO REMEDIES corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About MEDICO REMEDIES: business, sector, key facts.
What MEDICO REMEDIES does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
MEDICO REMEDIES operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: MEDICO, BSE: 540937.
Medico Remedies Limited is an Indian pharmaceutical company engaged in the development, manufacturing, and sale of a diverse range of pharmaceutical and nutraceutical products. Their operations encompass a wide spectrum of therapeutic areas, catering to various healthcare needs within the Indian market and beyond.
The company's product portfolio is extensive and includes a substantial number of therapeutic categories. This broad range covers antibiotics and anti-infectives, encompassing beta-lactams such as penicillins and cephalosporins, as well as antifungals. They also offer a significant selection of vitamins and supplements, addressing the growing demand for nutritional support. Further bolstering their offerings are cardiovascular products, pain management solutions (antipyretics, analgesics, and NSAIDs), gastrointestinal medications (antacids and anti-ulcer drugs), and treatments for mental health conditions (antidepressants, antipsychotics, and anti-epileptics). In addition, they produce antimalarials, various formulations like dry syrups, ointments, and creams, alongside anti-diabetics and other miscellaneous products.
Beyond their core offerings, Medico Remedies also manufactures and sells diuretics, antiretrovirals, and steroidal preparations, demonstrating a commitment to providing a comprehensive suite of healthcare solutions. This wide-ranging inventory highlights their strategic positioning within the competitive pharmaceutical landscape. The company's commitment extends beyond the domestic market, as evidenced by their active involvement in exporting their products to international destinations, expanding their reach and market share.
Established in 1994 and headquartered in Mumbai, India, Medico Remedies Limited has a history of providing a diverse array of pharmaceutical and nutraceutical products. Their comprehensive product portfolio, combined with their export activities, positions them as a significant player in the Indian and global pharmaceutical industry. The company's continued success hinges on its ability to innovate, adapt to evolving market demands, and maintain its commitment to providing high-quality healthcare solutions.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about MEDICO REMEDIES (MEDICO).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of MEDICO REMEDIES (MEDICO)?
The current share price of MEDICO REMEDIES (MEDICO) is ₹39.87. Today, the stock has gained by ₹0.37 (0.94%), trading in a range of ₹39.00 to ₹40.19. The stock opened at ₹39.40 with a trading volume of 52,932 shares.
02Is MEDICO REMEDIES stock a good investment for long-term?
MEDICO REMEDIES can be considered for long-term investment based on several factors. The company has a market capitalization of ₹329.36 Cr., P/E ratio of 26.66, ROE of 17.38%, and ROCE of 15.61%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of MEDICO REMEDIES stock?
The 52-week high price of MEDICO REMEDIES (MEDICO) is ₹56.88, while the 52-week low is ₹30.22. Currently trading at ₹39.87, the stock is 31.93% above its 52-week low and 29.91% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy MEDICO REMEDIES stock at the current price?
Whether to buy MEDICO REMEDIES stock at ₹39.87 depends on multiple factors. The stock is currently trading with a P/E ratio of 26.66 and P/B ratio of 4.86. Today's performance shows a gain of 0.94%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of MEDICO REMEDIES and when is the next dividend?
MEDICO REMEDIES offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹39.87, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of MEDICO REMEDIES?
MEDICO REMEDIES's key financial metrics include: P/E Ratio: 26.66, P/B Ratio: 4.86, ROE: 17.38%, ROCE: 15.61%, Dividend Yield: 0%, EPS: ₹0.30, Book Value: ₹9.10, and Debt-to-Equity: 0.25. The company's market cap stands at ₹329.36 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is MEDICO REMEDIES stock performing today in the market?
MEDICO REMEDIES stock opened at ₹39.40 and is currently trading at ₹39.87, showing a gain of ₹0.37 (0.94%). The intraday high is ₹40.19 and low is ₹39.00. The trading volume stands at 52,932 shares, indicating moderate market participation today.
08What is the P/E ratio of MEDICO REMEDIES and what does it indicate?
MEDICO REMEDIES has a Price-to-Earnings (P/E) ratio of 26.66, which means investors are willing to pay 26.66 for every ₹1 of earnings. With an EPS of ₹0.30, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about MEDICO REMEDIES (MEDICO) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.